

16:00-17:30 Στρογγυλή Τράπεζα

Ο ρόλος του εργαστηρίου ύπνου: πέρα από τους ασθενείς με σύνδρομο απνοιώνυποπνοιών


- Ο ρόλος του εργαστηρίου ύπνου σε ασθενείς με νευρομυϊκά νοσήματα
- Ο ρόλος του εργαστηρίου ύπνου σε ασθενείς με σύνδρομο παχυσαρκίαςυποαερισμού
- Ο ρόλος του εργαστηρίου ύπνου σε ασθενείς με καρδιακή ανεπάρκεια
- Μη αναπνευστικές διαταραγές του ύπνου


Ο ρόλος του εργαστηρίου ύπνου σε ασθενείς με καρδιακή ανεπάρκεια

Βλάμη Αικατερίνη

Εργαστήριο Μελέτης Ύπνου Πανεπιστημιακό Γενικό Νοσοκομείο ΑΤΤΙΚΟΝ







Current prognosis is poor: 50% of all patients with CHF die within 5 years of diagnosis and less than 15% survive more than 10 years (Rosamond et al, 2007, Tendera, 2005

26 million patients Worldwide with 1million hospitalizations annually in the United States and Europe (Remme et al. 2001; Ambrosy e t al. 2014)


- HF affects 1–2% of the adult population in developed countries
- In the United States, it is estimated that more than 6.5 million people have HF
- The incidence of HF increases along with higher age, and in the age group of 70 years and older more than 10% have the condition
- 50–80% of the HF population have breathing sleep disorder
- · HF patients are often unaware of the presence of sleep disorders
- The role of sleep lab is very important in HF patients because of the need to inform the cardiologists about this coexistence of this disorder

Clinical Profile of HF patients


- Insomnia
- Obstructive Sleep apnea/Periodic Breathing
- PLMs
- RLS
- Daytime Sleepiness
- Fatigue
- Nocturnal dyspnea
- Nocturia
- Atrial Fibrilation


Drugs for heart failure


B-Blockers
decrease
nocturnal
production of
melatonin





HF patients do not have the same clinical presentation as the typical OSA /CSA CSR patients














Nature Reviews | Cardiology





In HFrEF, there is an association between the presence of CSA and an increased risk of ventricular arrhythmias





Adv Exp Med Biol - Advances in Internal Medicine DOI 10.1007/5584_2018_146 © Springer International Publishing AG 2018





Fig. 3 Sleep stages in patients with heart failure and reduced ejection fraction, overall and by type of sleep-disordered breathing (OSA obstructive sleep apnea and CSA central sleep apnea). REM rapid eye movement

Cardiologists should be concerned with the possibility that their patient's cardiac condition might be caused or aggravated by Sleep Apnea



Patients with HF have a moderate or high probability of OSA, screening all AF and heart failure patients with home sleep apnea testing might prove to have the highest utility


Clinical symptom-based questionnaires have been proposed to help identify patients who should be formally assessed for Sleep Apnea, but these tools have been proven to have disappointing utility in HF

Sleep Apnea Heterogeneity, Phenotypes, and Cardiovascular Risk

Symptom Subtypes of Obstructive Sleep
Apnea Predict Incidence of
Cardiovascular Outcomes

Clinical Symptoms
Subtypes of Sleep
Apnea

PSG metrics
AHI
Oxygen Desaturation
Arousal Index
Heart Rate
Variability



Sleep Apnea Heterogeneity, Phenotypes, and Cardiovascular Risk

- Symptoms
- <u>Physiologic traits</u> linked to disease pathogenesis
- Polysomnographic expression of this Breathing Sleep Disorder (e.g., severity of hypoxemia and sleep architectural changes)
- AHI is not the best predictor of OSA-related morbidity, and the field is now questioning the use of the AHI as the primary diagnostic or prognostic criterion for patients with sleep-disordered breathing
- REM sleep apnea and <u>hypoxic burden</u> significantly <u>increase cardiovascular risk</u> in patients with sleep apnea
- Various health outcomes may be related to sleep apnea through distinct pathophysiologic pathways that <u>differentially reflect responses to hypoxemia</u>, <u>arousal</u>, and <u>sleep state</u>

NEW PSG INDICES

Hypoxic Burden

A measure for enhanced prediction of OSA related cardiovascular mortality

The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study

European Heart Journal 2018

Obstruction Severity

Stronger relationship with increase mortality rate than AHI, especially among severe OSA patients

Muraja-Murro A et al The severity of individual obstruction events is related to increased mortality rate in severe obstructive sleep apnea J Sleep Res 2013

Adjusted-AHI

was further shown to be an independent risk factor for all-cause mortality and non-fatal cardiovascular events

Leppanen T et al RemLogic plug-in enables clinical application of AHI adjusted for severity of individual Obstruction events. J Med Eng Technol 2016



The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study

Ali Azarbarzin¹*, Scott A. Sands¹, Katie L. Stone^{2,3}, Luigi Taranto-Montemurro¹, Ludovico Messineo¹, Philip I. Terrill⁴, Sonia Ancoli-Israel^{5,6}, Kristine Ensrud⁷, Shaun Purcell^{1,8}, David P. White¹, Susan Redline¹, and Andrew Wellman¹

> **ICSM** Iournal of Clinical Sleep Medicine

J Clin Sleep Med. 2019:

SCIENTIFIC INVESTIGATIONS

of Cardiology

Severity of Desaturations Reflects OSA-Related Daytime Sleepiness Better Than AHI

Samu Kainulainen, MSc1,2,3; Juha Töyräs, PhD1,2,4; Arie Oksenberg, PhD5; Henri Korkalainen, MSc1,2; Sandra Sefa, MSc2; Antti Kulkas, PhD1,3; Timo Leppänen, PhD1,2

B30 SRN: BIG DATA ANALYSIS AND POPULATION BASED STUDIES / RAPiD: Rapid Abstract Poster Discussion Session / Monday, May 20/9:15 AM-11:15 AM / Room C140/C142 (Level 1), KBHCCD

Hypoxic Burden Predicts Incident Heart Failure in Adults with Sleep Apnea: The Sleep Heart Health Study

A. Azarbarzin, S. A. Sands, L. Taranto Montemurro, D. Vena, T. Sofer, S. Kim, D. P. White, D. Wellman, S. S. Redline; Division of Sleep and Circadian Disorders, Brigham and Women's

Corresponding author's email: aazarbarzin@bwh.harvard.edu

Hospital and Harvard Medical School, Boston, MA, United States.

burden confers greater risk of cardiovascular (CV) mortality independent of OSA severity (apneahypopnea index, AHI) and other known confounders (Azarbarzin et al., 2018). Here we assessed whether elevated hypoxic burden is associated with incident heart failure and compared it with apnea-hypopnea index (AHI). Methods: The sample was derived from the Sleep Heart Health Study (SHHS), which included 5036 middle-aged and older adults (53.4% women), age:

Rationale: We recently showed that greater obstructive sleep apnea (OSA)-associated hypoxic

63.9±11.2 years. The outcome was incident congestive heart failure. The hypoxic burden was determined by measuring the respiratory event-associated area under the desaturation curve from pre-event baseline. Baseline polysomnography was manually annotated for conventional parameters, including AHI (hypopneas associated with ≥3% oxygen desaturation), and percent time with oxygen saturation below 90% (T90). Several Cox proportional hazards regression models were used to calculate the hazard ratios after adjusting for age, BMI, race, gender,

smoking status, and comorbidities, including COPD, diabetes, hypertension, cardiovascular disease, and prevalent heart failure (Figure 1). Hypoxic burden, AHI, and T90 were natural log-transformed and then modeled. Results: Over the follow-up period (10.2±3.5 years), 618 (12.2%) individuals experienced incident heart failure. The mean (±SD) AHI and hypoxic burden were 13.7±14.8 events/hour and 50.5±57.8 %min/hour (Hypoxic burden of 50%min/hour is equivalent

individuals experienced incident heart failure. The mean (±SD) AHI and hypoxic burden were 13.7±14.8 events/hour and 50.5±57.8 %min/hour (Hypoxic burden of 50%min/hour is equivalent to 10 minutes of 5% desaturation below baseline every hour). The hypoxic burden predicted increased risk of incident heart failure in this sample in both minimally and fully adjusted models (Figure 1). In the fully adjusted, for every two-fold increase in the hypoxic burden, the risk of

incident heart failure increased by 14.3%. In contrast, the association between AHI and incident

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

11.19 Sleep disturbance and sleep-disordered breathing

Patients with HF frequently have sleep disturbance; the causes are many, including pulmonary congestion (leading to orthopnea and paroxysmal nocturnal dyspnoea) and diuretic therapy causing nocturnal diuresis. Anxiety and other psychological problems can also lead to insomnia, and reviewing sleep history is part of the holistic care of patients with HF (see Section 14). Up to one-third of patients with HF have sleep-disordered breathing. 211,212 Sleep apnoea is of concern in patients with HF because it leads to intermittent hypoxaemia, hypercapnia, and sympathetic excitation. Obstructive sleep apnoea also causes recurrent episodes of negative intrathoracic pressure and increases in LV afterload. It is more common in patients who are obese and whose sleeping partners report that the patient snores or exhibits daytime somnolence (the patient may not be aware of these). However, not all patients with obstructive sleep apnoea are obese. The prevalence of central sleep apnoea (including Cheyne-Stokes respiration) in HF is uncertain and may have declined since the widespread use of betablockers and CRT. Screening for and the diagnosis and treatment of sleep apnoea is discussed in detail elsewhere. 211,212 Diagnosis currently requires overnight polysomnography. Nocturnal oxygen supplementation, continuous positive airway pressure, bi-level positive airway pressure, and adaptive servo-ventilation may be used to treat nocturnal hypoxaemia.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2016				

Heart failure and sleep disorders

May 2016

Gianfranco Parati¹⁻³, Carolina Lombardi^{1,2}, Francesco Castagna^{1,2,4}, Paola Mattaliano^{1,2}, Pasquale Perrone Filardi⁵ and Piergiuseppe Agostoni^{6,7} on behalf of the Italian Society of Cardiology (SIC) Working Group on Heart Failure m

Box 2 | Epidemiology of sleep-disordered breathing

Prevalence of sleep disorders in patients with heart failure compared with the general population

Obstructive sleep apnoea^{20,21,26,27}:

11-38% versus 2-26%

Central sleep apnoea/Cheyne-Stokes respiration^{26-28,30-33,194}:

28-82% versus <5%

Chronic insomnia²:

33% versus 10-15%







- Full Polysomnography
- Unattended Polysomnography
- Home Sleep Testing
- Cardiorespiratory monitoring during sleep
- Nocturnal Oximetry
- Bedsided tesing during hospital staying
- Titration of the positive upper airway devices

?Splitnight in HF because of different attitude of HF patients at the beginning of sleep and the end of sleep

AHI, ODI, T90, Desaturation burden, Arousal index, Sleep Efficiency, WASO, Heart Rate Variability

Follow-up the response of patients with CHF to standard treatments and alternative treatments (CPAP or oxygen)


PSG should be used to assess the response after atrial pacing in patients with CHF and sleep apnea (possibly via improved chronotropic performance)

Polysomnogaphy is the best test to investigate symptoms of orthopnea and paroxysmal nocturnal dyspnea, particularly when there is doubt as to the degree of cardiac failure.

SPECIAL ARTICLES

Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline

Figure 2—Clinical algorithm for implementation of clinical practice guidelines.



Home Sleep Apnea Testing for the Diagnosis of Obstructive Sleep Apnea in Adults

Journal of Clinical Sleep Medicine, Vol. 13, No. 3, 2017

Recommendation 2: We recommend that polysomnography, or home sleep apnea testing with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA. (STRONG)

Recommendation 3: We recommend that if a single home sleep apnea test is negative, inconclusive or technically inadequate, polysomnography be performed for the diagnosis of OSA. (STRONG)

Uncomplicated patient =

Conditions that place the patient at increased risk of nonobstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation and sleep related hypoxemia). Examples of these conditions include significant cardiopulmonary disease Journal of Clinical
Sleep Medicina

Journal of Clinical Sleep Medicine, Vol. 1, No. 1, 2005

PRO/CON DEBATE

Routine Polysomnography is Indicated in Congestive Heart Failure

Matthew T. Naughton, M.D.

Monash University and Alfred Hospital, Melbourne, Victoria, Australia

In summary, routine polysomnography is required in patients with CHF in order to classify presence and type of SDB, plus response to treatment.

ELSEVIER

Canadian Journal of Cardiology 31 (2015) 935-939

Point/Counterpoint

Should All Congestive Heart Failure Patients Have a Routine Sleep Apnea Screening? Pro

Frédéric Sériès, MD

Should All Congestive Heart Failure Patients Have a Routine Sleep Apnea Screening? Con

Yanru Li, MDa, Lori B. Daniels, MD, MAS, FACCb, Patrick J. Strollo Jr., MD, FCCP, FAASMc, and Atul Malhotra, MDd

Can J Cardiol. 2015

Is There a Need to Routinely Assess for the Presence of

Pro

- Non typical symptoms, difficult to distinguish from nonspecific symptoms such as fatigue in HF
- Comorbid conditions such as refractory hypertension, absence of arterial pressure nocturnal dipping, atrial fibrillation, diastolic dysfunction, and hypocapnia are associated with an increase in the risk of SDB but are not sufficient to establish a diagnosis on their own
- Before heart transplantation
- Follow-up the response of patients with CHF to treatments which include both standard to the extravagant (biventricular pacing, transplantation, left ventricular assist devices) and alternative treatments (positive airway pressure or oxygen)

Point/Counterpoint

Should All Congestive Heart Failure Patients Have a Routine Sleep Apnea Screening? Pro

Frédéric Sériès, MD

Table 1. Main rationales that justify the for the need to identify the presence of sleep disturbances in CHF patients

SDB-associated risks in CHF patients

Benefits of treatment of SDB in CHF patients


- Ventricular arythmia^{1,7,8}
- Increase in cardiac readmission in a cardiology clinical unit²
- Reduced life expectancy^{3-6,9}
- Improvement in left ventricular ejection fraction¹²
- Improvement in mortality¹⁴
- Decrease in the rate of hospital readmission or consultation to emergency department after a cardiac event¹³

CHF, congestive heart failure; SDB, sleep-disordered breathing.

Is There a Need to Routinely Assess for the Presence of SDB in Congestive HF?

Con

- Use of routine screening for SDB include cost considerations and poor adherence of CHF patients to positive pressure therapy
- Accute ill HF do not need screening for SDB but only treatment with positive airway devices
- Portable sleep monitoring is increasing in popularity for the diagnosis of SDB in patients with HF (Woehrle H, et al. Determining the prevalence and predictors of sleep disordered breathing in patients with chronic heart failure: rationale and design of the SCHLA-HF registry. BMC Cardiovasc Disord. 2014)
- A careful history can help with case-finding and potentially reduce the need for screening of truly asymptomatic individuals with HF
- Data suggest that breathing abnormalities might be related to inadequate medical therapy rather than an independent issue requiring intervention (Solin et al. Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation. 1999)
- Diagnosis of OSA or CSA do not change management in HF patients



E 11. Comparative Survival of 258 HF Patients Treated for Sleep Apnea and 30,000 Not Tested for Sleep Apnea

In the largest observational study of about 30,000 Medicare beneficiaries newly diagnosed with HF, treatment of SDB was associated with decreased readmission, health care cost, and mortality

Common clinical characteristics and diagnosis of obstructive sleep apnoea

Obstructive sleep apnoea

Clinical characteristics

- Unexplained daytime somnolence¹⁹⁵
- Abnormal sleep noises¹⁹⁶ (gasping, choking, loud apnoeas) with respiratory effort witnessed by bed partners
- Fatique¹⁹⁵
- Resistant arterial hypertension⁴⁵
- Cardiac rhythm abnormalities 197
- Obesity/high waist and neck circumference¹⁹⁸
- Narrow oropharynx¹⁹⁹
- Heart failure symptoms, in particular peripheral oedema²⁰⁰

Obstructive sleep apnoea Diagnosis

- ≥5 predominantly obstructive respiratory events (obstructive and mixed apnoeas, hypopnoeas, or respiratory effort related arousals) per hour of sleep, and at least one of the following:
- Sleepiness, nonrestorative sleep, fatigue, or insomnia symptoms
- Waking up with breath holding, gasping, or choking
- Habitual snoring, breathing interruptions, or both noted by a bed partner
- Presence of hypertension, mood disorder, cognitive dysfunction, coronary artery disease, stroke, congestive heart failure, atrial fibrillation, or type 2 diabetes mellitus

Or:

 ≥15 predominantly obstructive respiratory events (apnoeas, hypopnoeas, or respiratory effort related arousals) per hour of sleep — even in absence of the associated symptoms or comorbidities

Common clinical characteristics and diagnosis of central sleep apnoea

The principal risk factors for CSA/Cheyne–Stokes respiration in patients with HF identified in cross sectional studies are male sex, advanced age, hypocapnia, atrial fibrillation, or presence of a pacemaker, but not obesity

Central sleep apnoea

Clinical characteristics

- Rarely daytime somnolence¹²⁹
- Repetitive sleep apnoeas without abnormal noises, and without respiratory effort¹⁹³
- Poor quality of sleep²⁰¹
- Possible association with periodic breathing during exercise¹¹⁸
- Cardiac rhythm abnormalities¹⁹⁷
- Heart failure symptoms, in particular peripheral oedema²⁰⁰

Central sleep apnoea

 ≥5 central apnoeas and/or central hypopnoeas per hour of sleep; the number of central apnoeas and/ or central hypopnoeas needs to be >50% of the total number of apnoeas and hypopnoeas

Diagnosis¹

 Cheyne–Stokes breathing ventilation pattern; in the absence of this element and of daytime or nocturnal hypoventilation, the disorder is considered primary central sleep apnoea

And:


 At least one of the following: sleepiness, difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep; awakening with shortness of breath; snoring, witnessed apnoea

Or:

 Presence of atrial fibrillation or flutter, congestive heart failure, or a neurological disorder

And:


• The disorder is not better explained by another current sleep disorder, medication use, or substance use disorder



phases of hyperventilation alternate with central apnoeas and are characterised by cessation of airflow in the absence of as compensatory breathing efforts during the apnoea. Plus, unlike in OSA, in CSA-CSR, arousals are not closely linked to the elapnoea.

Cheyne Stokes Respiration





(A) Schematic of Cheyne-Stokes breathing (airflow shown) with a minimum of 3 consecutive central apneas (effort not shown) separated by a crescendo-decrescendo pattern of breathing. (B) Cheyne-Stokes breathing with central apneas (only airflow shown) with a long cycle time of 80 seconds. (C) Cheyne-Stokes breathing with central hypopneas (airflow shown). Although respiratory effort is not shown, these are central hypopneas with no evidence of airflow limitation (no flattening). As it is difficult to identify a beginning or end of the hypopnea, cycle time is defined as the time from one zenith in airflow during the respiratory phase to the next zenith in airflow.

PAP -HF




Fig. 3. Effect of positive airway pressure

Upper panels: Positive airway pressure widens an upper airway and pulmonary alveoli.

Lower panels: Positive end-expiratory pressure expands pulmonary alveoli, decreases pulmonary fluid and improves congestion and gas exchange in patients with heart failure.

Table 4 Actions of continuous positive airway pressure in CHF

Scenario	Acute pulmonary oedema	OSA	CSA-CSR
<mark>Upper airway</mark>			
Pneumatic splinting	+	+++	+
<u>Pulmonary</u>			
Overcome negative ITP	+	+++	+
<mark>In</mark> crease lung volume	++	++	++
Prevent alveolar collapse	<mark>+++</mark>	+	++
Improve VQ matching	<mark>+++</mark>	+	++
Reduce pulmonary vasoconstriction	<mark>+++</mark>	+	++
Assist inspiratory muscles	<mark>+++</mark>	+	++

Table 4 Actions of continuous positive airway pressure in CHF

Scenario	Acute pulmonary oedema	OSA	CSA-CSF
<u>Cardiac</u>			
Afterload reduction			
Less negative ITP	+	+++	+
Fall in systemic BP	+	++	++
Reduced LV diameter	+	++	++
Preload reduction	++	+	+

Current and potential treatments for sleep-disordered breathing


Treatment	Evidence
Obstructive sleep apnoea	
Noninvasive positive airway pressure:	Strong evidence
 Continuous positive airway pressure Bilevel positive airway pressure 	
Weight loss	Strong evidence provided by large interventional and observational studies
Mandibular advancement devices	Small studies, controversial evidence
Uvulopalatopharyngoplasty and laser assisted uvulopalatoplasty	Small studies
Furosemide and spironolactone	Preliminary results
Hypoglossal nerve stimulation	Preliminary results
Cardiac pacing	Potential treatment, but negative results have been obtained

HF-OSA-CPAP?

- RCTs involving patients with HF and OSA treated with CPAP showed an improvement in left ventricular systolic function and reductions in blood pressure, heart rate, and sympathetic nerve activity (Kaneko, Y. et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N. Engl. J. Med.2003, Mansfield, D. R. et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am. J. Respir. Crit. Care Med. 2004)
- 2 observational studies show that CPAP treatment lowers mortality and improves hospitalization free survival in patients with HF, particularly in compliant patients (use CPAP 4.9 h) (Kasai, T. et al. Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. Chest 2008)
- Until now, there is no RCT to evaluate the effects on mortality of CPAP treatment for OSA in HF
- AHA/ACC Foundation considers CPAP in HF as being investigational because this treatment option is not supported by RCTs data

Based on the available evidence, it is reasonable to recommend PAP therapy for the improvement of symptoms in patients with OSA but not for protection against vascular disease or death. It is possible that an enhanced evidence base able to better explore effects in patient subgroups might identify protective effects of PAP treatment for some patient subsets

SLEEP MEDICINE



Cumulative Event Free Survival (%)

Numbers at Risk

Treated

Untreated

60

40

20




Figure 2. Cumulative Event Curve of the Primary End Point.

Shown is the cumulative incidence of a first primary end point (a composite of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure, unstable angina, or transient ischemic attack) in the group that received CPAP plus usual care (CPAP group) and in the group that received usual care alone (usual-care group). The inset shows the same data on an enlarged y axis.

The NEW ENGLAND
JOURNAL of MEDICINE

ESTABLISHED IN 1812

SEPTEMBER 8, 2016

VOL. 375 NO. 1

Current and potential treatments for sleep-disordered breathing

Central sleep apnoea	Evidence
Noninvasive positive airway pressure:	
 Continuous positive airway pressure Bilevel positive airway pressure Adaptive pressure support servo-ventilation 	 Partly controversial evidence from small studies Partly controversial evidence from small studies Still under investigation
Acetazolamide and theophylline	Small observational studies
Supplemental O ₂	Controversial evidence
Phrenic nerve stimulation	Pilot studies, efficacy to be proven
Cardiac pacing	Small studies, more evidence needed

- CSA in HF should trigger attention to determine whether more aggressive therapy is required to combat the CHF
- Sleeping upright or laterally
- Greater afterload reduction (vasodilators), preload reduction with diuretics such as acetazolamide, inotropes, surgery (coronary artery graft surgery, valvular repair or replacement), rhythm correction, pacemakers [atrial overdrive, biventricular, left ventricular assist device or even heart transplantation,

HF-CSA-PAP???

- CPAP responders HF patients non CPAP responders HF patients
- CANPAP trial: HF and CSA at 3 months, the CPAP group showed a reduction in the AHI, increase of EF and mean Oxygen Saturation but no differences were found in the overall death (Bradley, T. D. et al. Continuous positive airway pressure for central sleep apnea and heart failure. N. Engl. J. Med. 2005)
- A post-hoc analysis showed a decrease in mortality in patients in whom CPAP resulted in amelioration of CSA (CPAP responders (Arzt, M. et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the CANPAP for Patients with Central Sleep Apnea and Heart Failure Circulation 2007)





Figure 3. Heart-Transplantation-free Survival.


There was no difference in transplantation-free survival rates between the control group and the CPAP group (hazard ratio for transplantation-free survival, 1.16; P=0.54). However, there was an early divergence in the event rates that favored the control group (hazard ratio for transplantation-free survival, 1.5; P=0.02) that altered after 18 months to favor the CPAP group (hazard ratio for transplantation-free survival, 0.66; P=0.06).


(CANPAP) trial N Engl J Med 2005;353:2025-33.

Transplant-free survival in HF patients according to effect of CPAP on CSA



The answer to the question of treating sleep-disordered breathing leading to improved heart failure outcomes is not clear







In conclusion, patients who had heart failure with a reduced ejection fraction and predominantly central sleep apnea, the addition of adaptive servo-ventilation to guideline-based medical treatment did not improve the outcome. The risk of **cardiovascular death was increased by 34%**, which was sustained through-out the trial, and there was no beneficial effect


on quality of life or symptoms of heart failure.


Cheyne Stokes Respiration in Heart Failure



3 Months After Treatment of Heart Failure Appearance Obstructive Hypopneas









Sleep – the yet underappreciated player in cardiovascular diseases: A clinical review from the German Cardiac Society Working Group on Sleep Disordered Breathing

European Journal of Preventive
Cardiology
0(00) 1–15
© The European Society of
Cardiology 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2047487319879526
journals.sagepub.com/home/cpr

\$SAGE





Figure 2. Schematic illustration of the association between sleep duration and the risk of developing or dying of total cardiovascular disease. While for self-reported sleep duration both long and short sleep duration are associated with an increased risk (black line), only short objective sleep duration is associated with an increased risk (red line). In fact, when sleep is measured objectively, short sleep and poor sleep quality, but not long sleep, is a risk factor for mortality.¹⁴

Insomnia symptoms, including having difficulty initiating sleep,
maintaining sleep, or having poor sleep quality, are highly prevalent
among heart failure (HF) patients. Recent studies indicate that the
prevalence of these symptoms among HF patients ranges from 23 to 73%

Little is known about sleep quality in patients with HF

The distribution of overnight sleep stages has a significant influence on autonomic function and is therefore directly relevant to cardiovascular medicine

Slow-wave (N3) sleep is associated with an increase in vagal tone, whereas REM sleep is associated with an increase in sympathetic neural traffic



gure 1. Representative polysomnogram showing healthy sleep architecture with characteristic and repetitive passage through eep cycles. N3 represents slow-wave sleep, which occurs more during the first half of the night, whereas REM sleep is more common Iring the second half of the night. Pathological sleep is characterised by a reduction in slow-wave sleep and/or REM sleep and/or sleep



Short sleep time and Low Sleep Quality

- 1. Sleep fragmentation
- 2. Nonrestorative sleep
- 3. Difficulties in initiating sleep
- 4. Waking up too early in the morning
- 5. Chronic Insomnia:
- -Primary or psychophysiologi-cal insomnia (mood disorders and psychological stress)
- -Secondary insomnia caused by the HF itself or by adverse effects of commonly prescribed HF medications, such as angiotensin- receptor blockers, loop diuretics, and B-blockers
- 6. Nocturia

HF, angiotensinreceptor blockers, loop diuretics, and β-blockers



Reduction in operating efficiency

Depression

Dementia

Unhealthy lifestyle

Abnormal autonomic nervous system

Abnormal neuroendocrine system

Obesity

Arteriosclerosis

Hypertension

Diabetes

Cardiovascular disease

Heart failure

Insomnia

Excessive daytime sleepiness

Reduction in operating efficiency

Depression

Daytime symptoms (fatigue, etc.)

Worsening functional performance

Activation of renin-angiotensinaldosterone system

Heart failure patients

Low QOL

Inadequate medication adherence


Increased risk of cardiac events

Primary or Psychophysiologi-cal Insomnia, Depression

Heart Failure

Sleep - the yet underappreciated player in cardiovascular diseases: A clinical review from the German Cardiac Society Working Group on Sleep Disordered Breathing

© The European Society Cardiology 2019 Article reuse guidelines sagepub.com/journals-permissions DOI: 10.1177/2047487319879526 (\$)SAGE



esumed complex pathophysiological interplay of sleep with various cardiovascular comorbidities. Arrows high t insufficient objective and/or high-quality data exist to support the notion of an association, while red arrow exist, making the association highly likely.


Prognostic Significance of Insomnia in Heart Failure

Circulation Journal

http://www.j-circ.or.jp

Official Journal of the Japanese Circulation Society

Yuki Kanno, MD; Akiomi Yoshihisa, MD, PhD; Shunsuke Watanabe, MD; Mai Takiguchi, MD; Tetsuro Yokokawa, MD; Akihiko Sato, MD; Shunsuke Miura, MD; Takeshi Shimizu, MD, PhD; Yuichi Nakamura, MD, PhD; Satoshi Abe, MD, PhD; Takamasa Sato, MD, PhD; Satoshi Suzuki, MD, PhD; Masayoshi Oikawa, MD, PhD; Shu-ichi Saitoh, MD, PhD; Yasuchika Takeishi, MD, PhD



Interestingly, it has that voluntary daytime naps of <2 hours have recently been shown to decrease sympatho-vagal balance in a similar way to that seen during slow-wave sleep

Whitehurst LN et al. Comparing the cardiac autonomic activity profile of daytime naps and nighttime sleep. Neurobiol Sleep Circadian Rhythm 2018

Cellini N et al. Heart rate variability during daytime naps in healthy adults: autonomic profile and short-term reliability. Psychophysiology 2016

On the contrary, spontaneous daytime naps that are highly prevalent in patients with cardiovascular diseases especially at durations longer than 30 minutes may have a compensatory role but they have beeen associated with unfavourable changes in the regulation of metabolic and endocrine hormones

The potential of melatonin administration for promoting sleep quality in HF patients has not been proved until now

In the future the demonstration of conservative measures such as teaching sleep hygiene or using behavioural therapy could improve sleep quality in patients with cardiovascular disorders

Prognostic Impact of Restless Legs Syndrome on Patients with Heart Failure

8.6% in HF patients had RLS

HF patients with RLS had a higher prevalence of anemia, higher levels of BNP, impaired cardiac function of the right and left ventricles

and sympathetic overactivity, activate the hypothalamic-pituitary-adrenal axis and increase the levels of pro-inflammatory cytokines and circulating catecholamine and all conditions leads to adverse prognosis of HF

CVD could produce RLS through vascular changes in the central nervous system or in the periphery or through the influence of medications (e.g., inotropic agents) for CVD. Thus, presence of RLS may present severity of CVD or HF

Relation of Periodic Leg Movements During Sleep and Mortality in Patients With Systolic Heart Failure

Dai Yumino, MD, PhD^{a,d}, Hanqiao Wang, MD^{a,d}, John S. Floras, MD, DPhil^{b,c}, Gary E. Newton, MD^b, Susanna Mak, MD, PhD^b, Pimon Ruttanaumpawan, MD^{a,d}, John D. Parker, MD^{b,c}, and T. Douglas Bradley, MD^{a,c,d,*}

Am J Cardiol 2011

37% of unselected patients with HF had PLMs at a rate of 5 per hour of sleep

compared with a prevalence of 4% to 8% in subjects without HF




Figure 2. Kaplan-Meier plots comparing survival between patients with HF with PLMIs ≥5 and those with PLMIs <5. *Adjusted HR for significant confounding factors included age, NYHA class, LVEF, ischemic cause of HF, and central sleep apnea.

Contents lists available at ScienceDirect


International Journal of Cardiology




iournal homepage: www.elsevier.com/locate/jicard

Correspondence

Prognostic significance of periodic leg movements during sleep in heart failure patients





Non-severe PLMS 96

Fig. 1. Comparison of cardiac mortality between the severe PLMS group and the nonsevere PLMS group, Kaplan-Meier analysis for cardiac mortality (severe PLMS vs. non-

Impact on Clinical Outcomes of Periodic Leg Movements During Sleep in Hospitalized Patients Following Acute Decompensated Heart Failure





Figure. Cumulative event-free survival curves in patients with acute decompensated heart failure and PLMI <30 or ≥30/h. Cumulative event-free survival from all-cause death and rehospitalizations was significantly better in patients without severe PLM (i.e., PLMI <30/h) compared with those with severe PLM (i.e., PLMI ≥30/h) (log-rank test; P=0.002). PLM.



ΣΥΜΠΕΡΑΣΜΑ

- Οι ασθενείς με HF εμφανίζουν πολύ συχνά διαταραχές ύπνου γι' αυτό θα
 πρέπει να αξιολογούνται στο Εργαστήριο Μελέτης Υπνου για τον καθορισμό της
 διαταραχής ύπνου που τυχόν εμφανίζουν με εξέταση εκλογής την
 Πολυπνογραφία
- Ειδικά η αναγνώριση και αντιμετώπιση των διαταραχών της αναπνοής στον ύπνο σε ασυμπτωματικούς ασθενείς με καρδιακή ανεπάρκεια αποτρέπει την εξέλιξη της καρδιακής νόσου σε βαρύτερες μορφές
- Οι εξετάσεις με τις φορητές συσκευές θα μπορούσαν να χρησημοποιηθούν στη διάγνωση των αναπνευστικών διαταραχών κατά περίπτωση (δεν υπάρχουν μέχρι τώρα επαρκή δεδομένα για τους ασθενείς με HF)
- Η συνεργασία του Καρδιολόγου με τον Ειδικό Ιατρό στην Ιατρική του Ύπνου αποτελεί απαραίτητη προυπόθεση για τη λήψη της τελικής θεραπευτικής απόφασης της αντιμετώπισης της διαταραχής ύπνου





16:00-17:30 Στρογγυλή Τράπεζα

Ο ρόλος του εργαστηρίου ύπνου: πέρα από τους ασθενείς με σύνδρομο απνοιώνυποπνοιών

Ευχαριστώ

Ο ρόλος του εργαστηρίου ύπνου σε ασθενείς με καρδιακή ανεπάρκεια

Βλάμη Αικατερίνη

Εργαστήριο Μελέτης Ύπνου Πανεπιστημιακό Γενικό Νοσοκομείο ΑΤΤΙΚΟΝ

